Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

G. Mannis · SciRah

Researcher profile · Semantic Scholar

G. Mannis

Share profile

G. Mannis — researcher profile on SciRah

h-index: 21
Works: 109
Citations: 3,675

Most-cited papers

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.
M. Tallman, Eunice S. Wang, J. Altman, F. Appelbaum +30 more
2019The Journal of the National Comprehensive Cancer Network371 citations Open access
Semantic Scholar
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
G. Roboz, C. Dinardo, E. Stein, S. de Botton +27 more
2019Blood347 citations Open access
Semantic Scholar
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
D. Pollyea, D. Bixby, A. Perl, V. Bhatt +30 more
2021The Journal of the National Comprehensive Cancer Network273 citations
Semantic Scholar
Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)
G. Issa, I. Aldoss, M. Thirman, John F. DiPersio +23 more
2024Journal of Clinical Oncology227 citations Open access
Semantic Scholar
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.
D. Pollyea, J. Altman, R. Assi, D. Bixby +33 more
2023The Journal of the National Comprehensive Cancer Network173 citations Open access
Semantic Scholar
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results
N. Daver, Paresh Vyas, S. Kambhampati, M. A. Al Malki +17 more
2023Journal of Clinical Oncology92 citations Open access
Semantic Scholar
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study
Martha L. Arellano, M. Thirman, J. Dipersio, M. Heiblig +32 more
2025Blood85 citations Open access
Semantic Scholar
Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy.
Bhagirathbhai R. Dholaria, B. Savani, B. Hamilton, B. Oran +25 more
2020Biology of Blood and Marrow Transplantation73 citations Open access
Semantic Scholar
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need.
N. Pemmaraju, H. Kantarjian, K. Sweet, Eunice S. Wang +56 more
2022Blood48 citations Open access
Semantic Scholar
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors
Yazan Numan, Zaid H. Abdel Rahman, J. Grenet, S. Boisclair +21 more
2022American journal of hematology/oncology47 citations Open access
Semantic Scholar
Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia
Amir T. Fathi, Alexander E. Perl, Geoffrey Fell, Brian A. Jonas +31 more
2025Blood46 citations
Semantic Scholar
Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results.
N. Daver, P. Vyas, S. Kambhampati, M. A. Al Malki +15 more
2022Journal of Clinical Oncology40 citations
Semantic Scholar
AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results
D. Sallman, A. Asch, S. Kambhampati, M. A. Al Malki +20 more
202138 citations
Semantic Scholar
NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Acute Myeloid Leukemia, Version 3.2019
M. Tallman, Eunice S. Wang, J. Altman, F. Appelbaum +31 more
201933 citations
Semantic Scholar
Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study
I. Aldoss, G. Issa, M. Thirman, J. Dipersio +22 more
2023Blood29 citations
Semantic Scholar
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience
Armon Azizi, A. Ediriwickrema, Ritika Dutta, Shyam A. Patel +8 more
2020Leukemia and Lymphoma29 citations
Semantic Scholar
Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia
I. Aldoss, G. Issa, J. Blachly, M. Thirman +24 more
2024Blood19 citations
Semantic Scholar
Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study
I. Aldoss, G. Issa, M. Thirman, J. Dipersio +22 more
2023Blood18 citations
Semantic Scholar
Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation
Emily C. Liang, Connie Chen, Rong Lu, G. Mannis +1 more
2021Bone Marrow Transplantation18 citations Open access
Semantic Scholar
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.
R. Shallis, Naval G. Daver, J. Altman, R. Komrokji +37 more
2023The Lancet Haematology16 citations
Semantic Scholar
Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin
Abdullah Ladha, G. Mannis, Lori S. Muffly
2020Leukemia and Lymphoma15 citations
Semantic Scholar
IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results
G. Mannis, A. Aribi, Neil Dunavin, H. Carraway +17 more
2024Blood12 citations
Semantic Scholar
Acute Myeloid Leukemia , Version 3 . 2019
M. Tallman, Eunice S. Wang, J. Altman, F. Appelbaum +31 more
201912 citations
Semantic Scholar
All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.
G. Roboz, A. Zeidan, G. Mannis, P. Montesinos +19 more
2026New England Journal of Medicine11 citations
Semantic Scholar
Older Adults With Newly Diagnosed AML: Hot Topics for the Practicing Clinician.
Catherine Lai, R. Bhansali, E. Kuo, G. Mannis +1 more
2023American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting10 citations Open access
Semantic Scholar
AML-464 Tolerability and Efficacy of the First-In-Class Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia (AML): Phase 1b Results.
N. Daver, P. Vyas, S. Kambhampati, M. A. Al Malki +15 more
2022Clinical Lymphoma, Myeloma & Leukemia10 citations
Semantic Scholar
S132: TOLERABILITY AND EFFICACY OF THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IN FRONTLINE PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: PHASE 1B RESULTS
N. Daver, P. Vyas, S. Kambhampati, M. A. Al Malki +15 more
2022HemaSphere10 citations Open access
Semantic Scholar
A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia
A. Aribi, G. Mannis, Y. Madanat, Brian A. Jonas +16 more
2025Blood neoplasia8 citations
Semantic Scholar
Outcomes with molecularly targeted agents as salvage therapy following frontline venetoclax + hypomethylating agent in adults with acute myeloid leukemia: A multicenter retrospective analysis.
V. Khanna, T. Azenkot, S. Liu, Jason S. Gilbert +7 more
2023Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis8 citations
Semantic Scholar
Venetoclax monotherapy for cutaneous blastic plasmacytoid dendritic cell neoplasm
M. Schwede, Irena T Tan, Danielle F Atibalentja, Meghan Dickman +2 more
2020Annals of Hematology8 citations
Semantic Scholar
Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations
N. Pemmaraju, Y. Madanat, D. Rizzieri, Salman Fazal +5 more
2024Leukemia and Lymphoma7 citations Open access
Semantic Scholar
An all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients (pts) with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy: Results from a phase 2 cohort of 101 pts.
A. Zeidan, Elizabeth A. Griffiths, C. Dinardo, G. Mannis +16 more
2025Journal of Clinical Oncology6 citations
Semantic Scholar
Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study
I. Aldoss, G. Issa, J. Blachly, M. Thirman +24 more
2025Blood6 citations
Semantic Scholar
p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes.
N. Brar, Lauren Lawrence, Eula Fung, James L. Zehnder +10 more
2024American Journal of Clinical Pathology6 citations
Semantic Scholar
Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia
G. Mannis, C. Abboud, N. Daver, G. Murthy +14 more
2025eJHaem5 citations Open access
Semantic Scholar
Prognostic Significance of CD123 Expression in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Bruce C. Tiu, Christina Su, Emma C. St Martin, Jean S. Oak +2 more
2024Blood5 citations
Semantic Scholar
Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all ‘non-adverse’ risk AML
Abdullah Ladha, Gavin Hui, Edna Cheung, C. Berubé +6 more
2020Leukemia and Lymphoma5 citations Open access
Semantic Scholar
Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML
N. Daver, K. Lee, Yunsuk Choi, P. Montesinos +30 more
2024Blood4 citations
Semantic Scholar
Cladribine and Low-Dose Cytarabine-Based Salvage Therapy for Relapsed/Refractory AML in a Predominantly Venetoclax-Exposed Cohort
Edna Cheung, C. Schumann, Tian Y. Zhang, B. Fakhri +4 more
2023Blood4 citations Open access
Semantic Scholar
V-FAST master trial: Preliminary results of treatment with CPX-351 plus midostaurin in adults with newly diagnosed FLT3-mutated acute myeloid leukemia.
J. Mccloskey, V. Pullarkat, G. Mannis, Tara L. Lin +9 more
2022Journal of Clinical Oncology4 citations
Semantic Scholar
V-FAST Master Trial: Subgroup Analysis of Outcomes with CPX-351 Plus Midostaurin in Adults with Newly Diagnosed Acute Myeloid Leukemia By FLT3 Mutation Type
J. Mccloskey, V. Pullarkat, G. Mannis, Tara L. Lin +8 more
2022Blood4 citations
Semantic Scholar
A Phase 1 Study Evaluating ASTX727 (decitabine and cedazuridine) and Venetoclax Combination Therapy in Newly Diagnosed AML Patients Unfit for Intensive Induction Chemotherapy
G. Mannis, E. Griffiths, M. Savona, O. Odenike +10 more
2021Blood4 citations
Semantic Scholar
Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.
Amir T. Fathi, Alexander E. Perl, Geoffrey Fell, Brian A. Jonas +37 more
2026New England Journal of Medicine3 citations
Semantic Scholar
NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.
D. Pollyea, Jessica K. Altman, R. Assi, K. Bachiashvili +35 more
2026The Journal of the National Comprehensive Cancer Network3 citations
Semantic Scholar
V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML
V. Pullarkat, M. Levis, James K. McCloskey, G. Mannis +10 more
2025Blood neoplasia3 citations
Semantic Scholar
CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123.
Xiao-Yi Hu, A. Ediriwickrema, Atif Saleem, Brent Tan +2 more
2024Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis3 citations
Semantic Scholar
Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial
D. DeAngelo, A. Schuh, Brian A. Jonas, Pamela S. Becker +21 more
2024Blood3 citations
Semantic Scholar
Acute Myeloid Leukemia with Inv(3) or t(3;3): A Clinical and Cytogenetic Characterization of 40 Patients
Maria Moscvin, M. Schwede, G. Mannis, Tian Y. Zhang
2023Blood3 citations Open access
Semantic Scholar
Preliminary Results By Age Group of Treatment with CPX-351 Plus Venetoclax in Adults with Newly Diagnosed AML: Subgroup Analysis of the V-FAST Phase 1b Master Trial
V. Pullarkat, M. Levis, G. Mannis, S. Strickland +6 more
2021Blood3 citations
Semantic Scholar
Tuscany Study demonstrates safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy
G. Mannis, N. Podoltsev, D. Jeyakumar, Justin M. Watts +10 more
2025Blood2 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Fathi×10
Invite
A. Fathi — researcher profile on SciRah
Alice S. Mims×10
Invite
Alice S. Mims — researcher profile on SciRah
N. Daver×10
Invite
N. Daver — researcher profile on SciRah
A. Perl×9
Invite
A. Perl — researcher profile on SciRah

×9

Invite

D. Pollyea — researcher profile on SciRah

S. Strickland×9

Invite

S. Strickland — researcher profile on SciRah

Invite

J. Altman — researcher profile on SciRah

Invite

V. Bhatt — researcher profile on SciRah

Invite

E. Stein — researcher profile on SciRah

Invite

I. Aldoss — researcher profile on SciRah

D. Jeyakumar×8

Invite

D. Jeyakumar — researcher profile on SciRah

Invite

M. Tallman — researcher profile on SciRah